Evofem Biosciences Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evofem Biosciences stock.
View analyst ratings for Evofem Biosciences or view top-rated stocks.

Wall Street analysts have given Evofem Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evofem Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Evofem Biosciences.

Evofem Biosciences, Inc. (NASDAQ:EVFM) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.07. The biotechnology company earned $1.11 million during the quarter, compared to analysts' expectations of $2.02 million.
View Evofem Biosciences' earnings history.

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVFM stock has decreased by 77.5% and is now trading at $1.16.
View which stocks have been most impacted by COVID-19.

4 analysts have issued 12-month price objectives for Evofem Biosciences' stock. Their forecasts range from $3.00 to $25.00. On average, they expect Evofem Biosciences' stock price to reach $9.25 in the next year. This suggests a possible upside of 697.4% from the stock's current price.
View analysts' price targets for Evofem Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Evofem Biosciences include TherapeuticsMD (TXMD), CytomX Therapeutics (CTMX), Flexion Therapeutics (FLXN), Avadel Pharmaceuticals (AVDL), MedAvail (MDVL), Athenex (ATNX), Akouos (AKUS), Spero Therapeutics (SPRO), Geron (GERN), Viracta Therapeutics (VIRX), BeyondSpring (BYSI), KemPharm (KMPH), Neoleukin Therapeutics (NLTX), Oramed Pharmaceuticals (ORMP) and Oncorus (ONCR).
View all of EVFM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), OrganiGram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Evofem Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.75%), Baker BROS. Advisors LP (2.62%), Heartland Advisors Inc. (2.58%), Caas Capital Management LP (2.27%), Great Lakes Advisors LLC (2.04%) and Geode Capital Management LLC (1.29%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Justin J File, Kelly Culwell, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier and William Walmsley Hall.
View institutional ownership trends for Evofem Biosciences.

EVFM stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Valeo Financial Advisors LLC, Northern Trust Corp, Commonwealth Equity Services LLC, UBS Group AG, and Nuveen Asset Management LLC.
View insider buying and selling activity for Evofem Biosciences or view top insider-selling stocks.

EVFM stock was acquired by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Baker BROS. Advisors LP, Great Lakes Advisors LLC, D. E. Shaw & Co. Inc., Laurion Capital Management LP, BlackRock Inc., Point72 Asset Management L.P., and SG Americas Securities LLC. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Justin J File, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier, and William Walmsley Hall.
View insider buying and selling activity for Evofem Biosciences or or view top insider-buying stocks.

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVFM stock can currently be purchased for approximately $1.16.

Evofem Biosciences has a market capitalization of $119.29 million and generates $450,000.00 in revenue each year. The biotechnology company earns $-142,310,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

Evofem Biosciences employs 147 workers across the globe.

The official website for Evofem Biosciences is www.evofem.com.

Evofem Biosciences is headquartered at 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130.

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]